2023-11-13 17:13:11 ET
More on SCYNEXIS
- Scynexis hit by FDA clinical hold on antifungal trials
- Scynexis recalling antifungal therapy on potential contamination
For further details see:
SCYNEXIS files to sell 32.5M shares2023-11-13 17:13:11 ET
For further details see:
SCYNEXIS files to sell 32.5M sharesMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...